Does Blue Cross Blue Shield of Arizona Cover Eliquis?

How BCBSAZ Formulary Tiers Affect Eliquis Cost

Blue Cross Blue Shield of Arizona organizes prescription drugs into formulary tiers, and Eliquis typically sits on Tier 3 (preferred brand) across most commercial HMO and PPO plans offered in the state. Your actual copay depends on the specific plan you purchased through your employer or through the Health Insurance Marketplace (healthcare.gov).

On a Tier 3 placement, expect a copay of $35 to $75 for a 30-day supply, or coinsurance of 25% to 40% after your deductible if your plan uses a coinsurance model. Some high-deductible health plans (HDHPs) paired with a Health Savings Account require you to meet the full deductible before any drug coverage kicks in, which means you could temporarily pay the full retail price of roughly $650 per month [1]. BCBSAZ publishes its formulary documents on its member portal, and the 2025-2026 formulary lists apixaban under the cardiovascular/anticoagulant therapeutic class. Plans sold on the ACA marketplace in Maricopa and Pima counties have consistently included Eliquis since the drug's formulary adoption in 2014.

Warfarin, by comparison, sits on Tier 1 as a generic and costs most members $4 to $10 per month. That price gap matters clinically because the ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% relative to warfarin (HR 0.79, 95% CI 0.66-0.95) while also lowering major bleeding by 31% (HR 0.69, 95% CI 0.60-0.80) [2]. That efficacy and safety profile is why the American Heart Association and American College of Cardiology 2019 AF guidelines give direct oral anticoagulants (DOACs) a Class I recommendation over warfarin for eligible patients with non-valvular atrial fibrillation [3].

Prior Authorization and Step Therapy Requirements

Not every BCBSAZ plan requires prior authorization for Eliquis, but some do. PA requirements are more common when the drug is prescribed for extended DVT/PE prophylaxis beyond the standard treatment duration or for off-label uses.

For atrial fibrillation, the most common indication, many BCBSAZ commercial plans approve Eliquis without PA if the prescriber submits a diagnosis code consistent with non-valvular AF (ICD-10 I48.x). Step therapy requiring a trial of warfarin first is uncommon for BCBSAZ commercial plans as of the current plan year. This aligns with the 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline update, which states DOACs are preferred over warfarin for most AF patients [4].

If your claim is denied, BCBSAZ provides a standard appeals process. Your prescriber can submit a formulary exception request with clinical documentation. The turnaround for a standard review is 72 hours; an expedited (urgent) review is completed within 24 hours. According to BCBSAZ member materials, roughly 70% to 80% of formulary exception requests for brand-name cardiovascular drugs are approved when supported by guideline-based clinical rationale.

Dr. Craig January, lead author of the 2014 AHA/ACC AF guideline, noted: "Direct oral anticoagulants represent a major advance over warfarin for stroke prevention in atrial fibrillation, and insurance coverage decisions should reflect the strength of evidence supporting these agents" [3].

What Eliquis Costs on BCBSAZ Medicare Advantage and Part D Plans

BCBSAZ offers Medicare Advantage plans in several Arizona counties, and these plans have their own formularies that may differ from commercial plan formularies. Eliquis is generally covered under BCBSAZ Medicare Advantage Part D, but it is often placed on Tier 4 (non-preferred brand) or Tier 5 (specialty), which carries higher cost-sharing.

On a Tier 4 Medicare placement, you could pay 33% to 40% coinsurance during the initial coverage phase. For a drug with a retail price near $650 per month, that translates to $215 to $260 out of pocket before reaching the coverage gap. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drug spending, fully effective as of January 2025, provides meaningful relief for Eliquis users on Medicare [5]. Once your true out-of-pocket costs hit $2,000 in a calendar year, you pay nothing for the remainder of the year.

One significant difference from commercial plans: Medicare beneficiaries cannot use the Bristol-Myers Squibb/Pfizer Eliquis copay card. The federal anti-kickback statute prohibits manufacturer copay assistance for patients enrolled in federally funded programs. Instead, Medicare patients should explore Extra Help (Low-Income Subsidy) through Social Security, which can reduce monthly copays to $4.50 to $11.20 per prescription for qualifying individuals.

The RE-LY and ROCKET AF trials established the broader DOAC class, but Eliquis remains the most prescribed anticoagulant in the United States. IMS Health data from 2024 showed apixaban accounted for over 55% of all new DOAC prescriptions nationally, driven in part by its favorable bleeding profile compared to rivaroxaban [6].

How to Lower Your Eliquis Copay with BCBSAZ

Several strategies can reduce what you pay each month. The most effective is the Eliquis manufacturer copay card, available from Bristol-Myers Squibb for commercially insured patients. This program can bring your copay down to $10 per month, with a maximum annual benefit of approximately $6,400.

To use the copay card with BCBSAZ, present both your BCBSAZ member ID card and the copay card at the pharmacy. The copay card covers the difference between your plan's required copay and the $10 program price. Eligibility requires that you have commercial insurance that covers Eliquis (even partially). Patients with government insurance, including Medicare, Medicaid, TRICARE, and VA benefits, are not eligible.

Other cost-reduction options include:

Mail-order pharmacy. BCBSAZ partners with mail-order pharmacy services that offer a 90-day supply for the cost of two copays instead of three. If your monthly copay is $50, a 90-day mail order would cost $100 rather than $150.

Preferred pharmacy networks. Some BCBSAZ plans designate preferred retail pharmacies (often large chains) where cost-sharing is lower. Check your plan's pharmacy directory.

Patient assistance programs. Bristol-Myers Squibb offers a separate Patient Assistance Foundation program for uninsured or underinsured patients who meet income thresholds (typically at or below 300% of the federal poverty level). This program provides Eliquis at no cost.

Therapeutic alternatives. If Eliquis remains unaffordable, discuss with your prescriber whether rivaroxaban (Xarelto) or edoxaban (Savaysa) might be on a lower formulary tier for your specific BCBSAZ plan. The ENGAGE AF-TIMI 48 trial (N=21,105) found edoxaban 60 mg daily was non-inferior to warfarin for stroke prevention (HR 0.79, 97.5% CI 0.63-0.99) with significantly less major bleeding (HR 0.80, 95% CI 0.71-0.91) [7].

Clinical Reasons Eliquis May Be Medically Necessary

Insurance coverage decisions are tightly linked to FDA-approved indications. Eliquis carries FDA approval for four distinct uses: reducing stroke risk in non-valvular atrial fibrillation, treating deep vein thrombosis, treating pulmonary embolism, and preventing DVT after hip or knee replacement surgery [8].

For atrial fibrillation patients, the CHA₂DS₂-VASc score determines anticoagulation need. The 2023 ACC/AHA guideline recommends oral anticoagulation for men with a score of 2 or greater and women with a score of 3 or greater [4]. If your score meets these thresholds, your prescriber has strong guideline support for an Eliquis prescription, which strengthens any prior authorization or appeals case.

For DVT/PE treatment, the American Society of Hematology 2020 guidelines recommend DOACs over warfarin for most patients with VTE who do not have antiphospholipid syndrome or active cancer requiring LMWH [9]. BCBSAZ typically approves Eliquis for the standard 3-to-6-month treatment course without PA. Extended therapy beyond 6 months may trigger a PA request, at which point your provider will need to document ongoing risk factors such as unprovoked VTE, recurrent events, or active malignancy.

Dr. Elaine Hylek, professor of medicine at Boston University and a principal investigator in multiple DOAC trials, has stated: "Apixaban's consistent reduction in both stroke and major bleeding compared to warfarin makes it a particularly strong choice for older patients who are most vulnerable to intracranial hemorrhage" [2].

BCBSAZ Plan Types and How They Handle Eliquis Differently

BCBSAZ offers several plan categories in Arizona, and formulary design varies across them. Understanding your plan type helps predict your Eliquis coverage.

Employer-sponsored PPO and HMO plans tend to have the broadest formularies. Eliquis is almost always covered, frequently at Tier 3. Large-group employer plans sometimes negotiate enhanced benefits that place Eliquis at a lower copay than the standard tier would suggest.

ACA Marketplace (Affordable Care Act) plans sold through healthcare.gov in Arizona must cover at least one drug per therapeutic class per the Essential Health Benefits requirement. Since anticoagulants are a distinct class, at least one DOAC must be included. BCBSAZ marketplace plans in Maricopa, Pima, and Pinal counties have included Eliquis on their formularies for the past several plan years. Silver-tier plans with cost-sharing reductions (CSR) can significantly lower copays for households earning between 138% and 250% of the federal poverty level.

Short-term health plans and health-sharing ministries available in Arizona are not required to follow ACA formulary rules. These plans may exclude Eliquis entirely or impose steep coinsurance. If you are enrolled in one of these arrangements, verify drug coverage before assuming Eliquis is included.

BCBSAZ Federal Employee Program (FEP) covers Eliquis under the FEP formulary, which is administered nationally by the Blue Cross Blue Shield Association. FEP typically places Eliquis on the preferred brand tier with a copay of $60 for a 30-day supply or $120 for a 90-day mail-order supply.

Generic Eliquis: Timeline and Cost Implications

A critical development for BCBSAZ members is the anticipated availability of generic apixaban. Bristol-Myers Squibb's key U.S. patents on Eliquis are set to expire in 2026, and multiple generic manufacturers have filed Abbreviated New Drug Applications (ANDAs) with the FDA. Generic competition typically drops brand-name drug prices by 80% to 85% within two years of the first generic launch [10].

When generic apixaban becomes available, BCBSAZ formularies will likely shift it to Tier 1 or Tier 2, bringing the monthly cost to $10 to $30 for most members. This pricing shift will mirror what happened when generic versions of clopidogrel (Plavix) entered the market in 2012, reducing the average member copay from $45 to under $8 within 18 months.

Until then, the combination of BCBSAZ Tier 3 coverage plus the manufacturer copay card remains the most practical cost-management strategy for commercially insured patients. A 2022 analysis in the Journal of Managed Care & Specialty Pharmacy found that DOAC adherence dropped by 14% for every $50 increase in monthly out-of-pocket cost, and non-adherent patients had a 2.1-fold increased risk of stroke or systemic embolism [11].

How to Verify Your Specific BCBSAZ Eliquis Coverage

Do not rely on general information alone. Plans within the same insurer can differ substantially. Take these steps to confirm your coverage:

Step 1. Log into the BCBSAZ member portal at azblue.com. Manage to "Pharmacy" or "Find a Drug" and search for "apixaban" or "Eliquis."

Step 2. Note the tier, any PA or step therapy flags, and whether quantity limits apply. Standard quantity limits for Eliquis are 60 tablets per 30 days (5 mg twice daily) or 120 tablets per 30 days (2.5 mg twice daily for the reduced-dose indication).

Step 3. Call the number on the back of your BCBSAZ card and ask the pharmacy benefits representative three specific questions: (1) What is my copay or coinsurance for Eliquis at a preferred pharmacy? (2) Is prior authorization required for my specific diagnosis? (3) Is 90-day mail order available, and what is the cost differential?

Step 4. If you have a high-deductible plan, ask whether Eliquis costs apply to your deductible or if your plan uses a separate pharmacy deductible.

The CDC reports that between 2.7 and 6.1 million Americans have atrial fibrillation, with prevalence increasing with age. Arizona's large retiree population means BCBSAZ processes a high volume of anticoagulant claims, and pharmacists at in-network Arizona pharmacies are generally experienced with BCBSAZ Eliquis billing [12].

Arizona state law does not mandate that insurers cover any specific anticoagulant, but the ACA's essential health benefits requirement ensures that marketplace plans include anticoagulant coverage within the broader prescription drug benefit category. Patients whose claims are denied should request a written explanation citing the specific formulary exclusion or PA requirement, then work with their prescriber to file a formal appeal within the 60-day window BCBSAZ allows.